Literature DB >> 15713901

Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cells.

Johnathan C Lai1, Luba Benimetskaya, Anastasia Khvorova, Sijian Wu, Emily Hua, Paul Miller, C A Stein.   

Abstract

In a previous study, we showed that G3139, an antisense phosphorothioate oligonucleotide that down-regulates the expression of Bcl-2 protein, did not cause chemosensitization of 518A2 melanoma cells. In this work, we show that G3139, and the 2-base mismatch, G4126, can initiate apoptosis in this and other melanoma cell lines as shown by increased cell surface Annexin V expression, typical nuclear phenotypic changes as assessed by 4',6-diamidino-2-phenylindole staining, activation of caspase-3 (but not caspase-8) and Bid, appearance of DEVDase (but not IETDase) activity, and cleavage of poly(ADP-ribose)-polymerase 1. Depolarization of the mitochondrial membrane occurs as a relatively late event. All of these processes seem to be substantially, but perhaps not totally, Bcl-2 independent as shown by experiments employing an anti-Bcl-2 small interfering RNA, which as shown previously down-regulated Bcl-2 protein expression but did not produce apoptosis or chemosensitization in melanoma cells. In fact, these G3139-induced molecular events were not dramatically altered in cells that forcibly overexpressed high levels of Bcl-2 protein. Addition of irreversible caspase inhibitors (e.g., the pan-caspase inhibitor zVAD-fmk) to G3139-treated cells almost completely blocked cytotoxicity. Examination of the time course of the appearance of caspase-3 and cleaved poly(ADP-ribose)-polymerase 1 showed that this could be correlated with the release of cytochrome c from the mitochondria, an event that begins only approximately 4 hours after the end of the oligonucleotide/LipofectAMINE 2000 5-hour transfection period. Thus, both G3139 and cytotoxic chemotherapy activate the intrinsic pathway of apoptosis in these cells, although Bcl-2 expression does not seem to contribute strongly to chemoresistance. These findings suggest that the attainment of G3139-induced chemosensitization in these cells will be difficult.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15713901

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  8 in total

1.  A pharmacologic target of G3139 in melanoma cells may be the mitochondrial VDAC.

Authors:  Johnathan C Lai; Wenzhi Tan; Luba Benimetskaya; Paul Miller; Marco Colombini; C A Stein
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-28       Impact factor: 11.205

Review 2.  Specific VDAC inhibitors: phosphorothioate oligonucleotides.

Authors:  C A Stein; Marco Colombini
Journal:  J Bioenerg Biomembr       Date:  2008-06       Impact factor: 2.945

3.  Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.

Authors:  Bo Yu; Yicheng Mao; Li-Yuan Bai; Sarah E M Herman; Xinmei Wang; Asha Ramanunni; Yan Jin; Xiaokui Mo; Carolyn Cheney; Kenneth K Chan; David Jarjoura; Guido Marcucci; Robert J Lee; John C Byrd; L James Lee; Natarajan Muthusamy
Journal:  Blood       Date:  2012-11-19       Impact factor: 22.113

4.  Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103.

Authors:  Charles M Rudin; Ravi Salgia; Xiaofei Wang; Lydia D Hodgson; Gregory A Masters; Mark Green; Everett E Vokes
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544

5.  G3139, an anti-Bcl-2 antisense oligomer that binds heparin-binding growth factors and collagen I, alters in vitro endothelial cell growth and tubular morphogenesis.

Authors:  C A Stein; Sijian Wu; Anatoliy M Voskresenskiy; Jin-Feng Zhou; Joongho Shin; Paul Miller; Naira Souleimanian; Luba Benimetskaya
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

6.  Phosphorothioate oligonucleotides block the VDAC channel.

Authors:  Wenzhi Tan; Yue-Hin Loke; C A Stein; Paul Miller; Marco Colombini
Journal:  Biophys J       Date:  2007-05-04       Impact factor: 4.033

Review 7.  Mitochondrial voltage-dependent anion channels (VDACs) as novel pharmacological targets for anti-cancer agents.

Authors:  Eriko Simamura; Hiroki Shimada; Toshihisa Hatta; Kei-Ichi Hirai
Journal:  J Bioenerg Biomembr       Date:  2008-06       Impact factor: 2.945

8.  Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents.

Authors:  C A Stein; J Bo Hansen; Johnathan Lai; SiJian Wu; Anatoliy Voskresenskiy; Anja Høg; Jesper Worm; Maj Hedtjärn; Naira Souleimanian; Paul Miller; Harris S Soifer; Daniella Castanotto; Luba Benimetskaya; Henrik Ørum; Troels Koch
Journal:  Nucleic Acids Res       Date:  2009-10-23       Impact factor: 16.971

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.